Daridorexant

sleep · nervous · Oral

Daridorexant, a sleep compound. Dual orexin receptor antagonist; shorter half-life (~8h) than suvorexant or lemborexant — designed to minimize… Oral half-life 8 h.

Dual orexin receptor antagonist; shorter half-life (~8h) than suvorexant or lemborexant — designed to minimize next-day residual sedation. FDA approved 2022 for chronic insomnia.

Pharmacokinetics

• Oral — t½ 8 h · F 62% · ka 3.891 h⁻¹ · Vd 31 L

Sources: PMID:39118245, PMID:31860301, PMID:34002356